{"pmid":32395217,"pmcid":"PMC7202345","title":"Covid-19 and Children with Immune Thrombocytopenia: Emerging Issues.","text":["Covid-19 and Children with Immune Thrombocytopenia: Emerging Issues.","Mediterr J Hematol Infect Dis","Lassandro, Giuseppe","Palladino, Valentina","Palmieri, Viviana Valeria","Amoruso, Anna","Del Vecchio, Giovanni Carlo","Giordano, Paola","32395217"],"journal":"Mediterr J Hematol Infect Dis","authors":["Lassandro, Giuseppe","Palladino, Valentina","Palmieri, Viviana Valeria","Amoruso, Anna","Del Vecchio, Giovanni Carlo","Giordano, Paola"],"date":"2020-05-13T11:00:00Z","year":2020,"_id":"32395217","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.4084/MJHID.2020.028","keywords":["children","covid-19","immune thrombocytopenia"],"topics":["Prevention"],"weight":1,"_version_":1666627827864174592,"score":9.490897,"similar":[{"pmid":32445664,"title":"COVID-19 as a cause of immune thrombocytopenia.","text":["COVID-19 as a cause of immune thrombocytopenia.","Med Mal Infect","Humbert, S","Razanamahery, J","Payet-Revest, C","Bouiller, K","Chirouze, C","32445664"],"journal":"Med Mal Infect","authors":["Humbert, S","Razanamahery, J","Payet-Revest, C","Bouiller, K","Chirouze, C"],"date":"2020-05-24T11:00:00Z","year":2020,"_id":"32445664","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.medmal.2020.05.003","keywords":["covid-19","sars-cov-2","immune thrombocytopenia"],"topics":["Case Report"],"weight":1,"_version_":1667600475858403328,"score":117.38077},{"pmid":32420612,"title":"COVID-19-associated immune thrombocytopenia.","text":["COVID-19-associated immune thrombocytopenia.","Thrombocytopenia is a risk factor for increased morbidity and mortality in patients with the new severe acute respiratory syndrome corona virus, SARS-CoV-2 infection (COVID-19 infection).(1) Thrombocytopenia in COVID-19 patients may be caused by disseminated intravascular coagulation (DIC), sepsis or drug-induced. Recently a single case report suggested immune thrombocytopenia (ITP) may be associated with COVID-19 infection.(2) ITP is a rare autoimmune disease characterized by a platelet count < 100x10(9) /L, leading to an increased bleeding risk.(3) Several risk factors have been described for ITP including environmental (e.g. infection, malignancy and drugs) and genetic predisposition.(4) We report here the first case series of three patients with ITP associated with COVID-19 infection.","Br J Haematol","Bomhof, G","Mutsaers, P G N J","Leebeek, F W G","Te Boekhorst, P A W","Hofland, J","Croles, F N","Jansen, A J G","32420612"],"abstract":["Thrombocytopenia is a risk factor for increased morbidity and mortality in patients with the new severe acute respiratory syndrome corona virus, SARS-CoV-2 infection (COVID-19 infection).(1) Thrombocytopenia in COVID-19 patients may be caused by disseminated intravascular coagulation (DIC), sepsis or drug-induced. Recently a single case report suggested immune thrombocytopenia (ITP) may be associated with COVID-19 infection.(2) ITP is a rare autoimmune disease characterized by a platelet count < 100x10(9) /L, leading to an increased bleeding risk.(3) Several risk factors have been described for ITP including environmental (e.g. infection, malignancy and drugs) and genetic predisposition.(4) We report here the first case series of three patients with ITP associated with COVID-19 infection."],"journal":"Br J Haematol","authors":["Bomhof, G","Mutsaers, P G N J","Leebeek, F W G","Te Boekhorst, P A W","Hofland, J","Croles, F N","Jansen, A J G"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32420612","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1111/bjh.16850","locations":["Thrombocytopenia","Thrombocytopenia"],"topics":["Case Report"],"weight":1,"_version_":1667254896710123520,"score":56.765446},{"pmid":32445584,"title":"Immune Thrombocytopenia during Pregnancy due to COVID-19.","text":["Immune Thrombocytopenia during Pregnancy due to COVID-19.","Am J Hematol","Tang, Man Wai","Nur, Erfan","Biemond, Bart J","32445584"],"journal":"Am J Hematol","authors":["Tang, Man Wai","Nur, Erfan","Biemond, Bart J"],"date":"2020-05-24T11:00:00Z","year":2020,"_id":"32445584","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1002/ajh.25877","topics":["Case Report"],"weight":1,"_version_":1667600475795488768,"score":50.246483},{"pmid":32330332,"title":"SARS-CoV-2 infection in children - Understanding the immune responses and controlling the pandemic.","text":["SARS-CoV-2 infection in children - Understanding the immune responses and controlling the pandemic.","In December 2019, a cluster of patients with severe pneumonia caused by a novel coronavirus (SARS-CoV-2) emerged in the city of Wuhan, China. The disease is now termed coronavirus disease 2019 (COVID-19). In the early reports, the patients were mainly middle-aged and elderly men, and children appeared to be less susceptible to this infection. With modern and efficient transportation, the disease quickly spread to almost all corners of the world and the mortality far exceeds that caused by severe acute respiratory syndrome (SARS) coronavirus or Middle East respiratory syndrome (MERS) coronavirus. As the number of children with COVID-19 gradually increases, the disease has been documented in premature babies, infants, children, and adolescents. Severe and fatal cases in children are relatively rare. The burden of disease in children has been relatively low, but the high proportions of asymptomatic or mildly symptomatic infections in children deserve careful attention. A clear understanding of the immune responses to the virus in children and the transmission potential of asymptomatic children is of paramount importance for the development of specific treatments and vaccine in order to effectively control the ongoing pandemic.","Pediatr Allergy Immunol","Lu, Xiaoxia","Xiang, Yun","Du, Hui","Wing-Kin Wong, Gary","32330332"],"abstract":["In December 2019, a cluster of patients with severe pneumonia caused by a novel coronavirus (SARS-CoV-2) emerged in the city of Wuhan, China. The disease is now termed coronavirus disease 2019 (COVID-19). In the early reports, the patients were mainly middle-aged and elderly men, and children appeared to be less susceptible to this infection. With modern and efficient transportation, the disease quickly spread to almost all corners of the world and the mortality far exceeds that caused by severe acute respiratory syndrome (SARS) coronavirus or Middle East respiratory syndrome (MERS) coronavirus. As the number of children with COVID-19 gradually increases, the disease has been documented in premature babies, infants, children, and adolescents. Severe and fatal cases in children are relatively rare. The burden of disease in children has been relatively low, but the high proportions of asymptomatic or mildly symptomatic infections in children deserve careful attention. A clear understanding of the immune responses to the virus in children and the transmission potential of asymptomatic children is of paramount importance for the development of specific treatments and vaccine in order to effectively control the ongoing pandemic."],"journal":"Pediatr Allergy Immunol","authors":["Lu, Xiaoxia","Xiang, Yun","Du, Hui","Wing-Kin Wong, Gary"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32330332","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1111/pai.13267","keywords":["sars-cov-2","children","coronavirus","immune response","pandemic"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Transmission","Mechanism"],"weight":1,"_version_":1666138494555127808,"score":46.49289},{"pmid":32374026,"title":"Practical guidance for the management of adults with Immune Thrombocytopenia during the COVID-19 pandemic.","text":["Practical guidance for the management of adults with Immune Thrombocytopenia during the COVID-19 pandemic.","This document aims to provide practical guidance for the assessment and management of patients with thrombocytopenia, with a particular focus on Immune Thrombocytopenia (ITP) during the COVID-19 pandemic. The intention is to support clinicians and, although recommendations have been provided, it is not a formal guideline. Nor is there sufficient evidence base to conclude that alternative approaches to treatment are incorrect. Instead, it is a consensus written by clinicians with an interest in ITP or coagulation disorders and reviewed by members of the UK ITP forum.","Br J Haematol","Pavord, S","Thachil, J","Hunt, B","Murphy, M","Lowe, G","Laffan, M","Makris, M","Newland, A","Provan, D","Grainger, J","Hill, Q","32374026"],"abstract":["This document aims to provide practical guidance for the assessment and management of patients with thrombocytopenia, with a particular focus on Immune Thrombocytopenia (ITP) during the COVID-19 pandemic. The intention is to support clinicians and, although recommendations have been provided, it is not a formal guideline. Nor is there sufficient evidence base to conclude that alternative approaches to treatment are incorrect. Instead, it is a consensus written by clinicians with an interest in ITP or coagulation disorders and reviewed by members of the UK ITP forum."],"journal":"Br J Haematol","authors":["Pavord, S","Thachil, J","Hunt, B","Murphy, M","Lowe, G","Laffan, M","Makris, M","Newland, A","Provan, D","Grainger, J","Hill, Q"],"date":"2020-05-07T11:00:00Z","year":2020,"_id":"32374026","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1111/bjh.16775","locations":["thrombocytopenia","GBR"],"countries":["United Kingdom"],"countries_codes":["GBR|United Kingdom"],"topics":["Prevention"],"weight":1,"_version_":1666138496463536128,"score":45.78182}]}